Faraday Pharmaceuticals

company

About

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$30M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2014
Number Of Employee
1 - 10
Operating Status
Active

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center.

The company was founded in 2014 and is located in Seattle, Washington.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$55M
Faraday Pharmaceuticals has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on Sep 20, 2019 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 20, 2019 Series B $25M 1 ARCH Venture Partners Detail
Sep 3, 2015 Series A $30M 1 Detail
Jul 23, 2014 Series A 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Faraday Pharmaceuticals is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Yes Series B